Sponsor pipeline

Spyre Therapeutics, Inc. clinical trial pipeline

Get alerts when Spyre Therapeutics, Inc.'s trials change

Data updated daily from ClinicalTrials.gov, last refresh 2026-10-20

What changed in the last 30 days

3 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 2 with minor changes only.

Notable

SPY072 · Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)

Recruitment opened

Also in this update: Trial sites expanded: 12 → 34 locations

Spyre Therapeutics, Inc.Phase 2 NCT07766005 Registry history of NCT07766005 on ClinicalTrials.gov (opens the registry)

Oct 19, 2026

Show 2 trials with minor changes only

Minor

SKYLINE-LTE · Long-acting Antibodies Alone and in Combinations for IBD

Trial sites expanded: 70 → 86 locations

And 2 more changes in the last 30 days

Spyre Therapeutics, Inc.Phase 2 NCT07652294 Registry history of NCT07652294 on ClinicalTrials.gov (opens the registry)

Oct 19, 2026
Minor

SKYLINE-UC · Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

Trial sites expanded: 267 → 271 locations

Spyre Therapeutics, Inc.Phase 2 NCT07012395 Registry history of NCT07012395 on ClinicalTrials.gov (opens the registry)

Sep 29, 2026

Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.

Active trials by phase

Phase 1		1
Phase 2		4

Disease areas by active trials

Ulcerative Colitis (2) · Ankylosing Spondylitis (1) · Hidradenitis Suppurativa (1) · Psoriasis (1) · Psoriatic Arthritis (1) · Rheumatoid Arthritis (1)

Get alerts when Spyre Therapeutics, Inc.'s trials change

Status changes, date slips, and new filings: detected daily, delivered to your inbox.

Start monitoring free